医药导报2012，Vol.31Issue(10)：1318-1321,4.DOI:10.3870/yydb.2012.10.022
索拉非尼治疗肾癌脑转移的疗效及安全性
Efficacy and Safety of Sorafenib in Patients with Renal Cell Carcinoma Brain Metastases
摘要
Abstract
Objective To evaluate safety and efficacy of sorafenib in patients with renal cell carcinoma brain metastases ( RCCBM). Methods Sorafenib-related adverse events and the clinical efficacy in RCCBM patients were retrospectively analyzed. The category, severity and turnover of sorafeinb-related adverse events were observed. Also, the disease control rate (DCR) , progression-free survival (PFS) and overall survival (OS) were analyzed. Results In the seven RCCBM patients treated with sorafenib, the most common adverse events were hand-foot syndrome, diarrhea, rash, hypertension, fatigue and alopecia. Most of the adverse events happened in mild to moderate degree, and were alleviated after corresponding treatment. No severe adverse events like intracranial hemorrhage happened. The DCR, median progress free survival and median overall survival were 57. 1% , 5 months and 16 months, respectively. Conclusion The safety of sorafenib in RCCBM patients is satisfying. After local treatment, patients can obtain long-term clinical benefit from sorafenib treatment.关键词
索拉非尼/肾癌脑转移/靶向治疗Key words
Sorafenib/ Renal cell carcinoma brain metastases/ Targeted therapy分类
医药卫生引用本文复制引用
杨琳,丁英俊,石磊,于世英..索拉非尼治疗肾癌脑转移的疗效及安全性[J].医药导报,2012,31(10):1318-1321,4.基金项目
湖北省自然科学基金资助项目(2011CDB213) （2011CDB213）
